Solomon, Benjamin J.

Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer

Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 3,381

First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer

Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 3,190

Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 1,964

Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer

Shaw, A. T., Kim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., et al. (2014) · New England Journal of Medicine

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 1,495

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

Solomon, B. J., Besse, B., Bauer, T. M., Felip, E., Soo, R. A., Camidge, D. R., Chiari, R., Bearz, A., Lin, C.-C., Gadgeel, S. M., et al. (2018) · The Lancet Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 791

Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer

Sequist, L. V., Soria, J.-C., Goldman, J. W., Wakelee, H. A., Gadgeel, S. M., Varga, A., Papadimitrakopoulou, V., Solomon, B. J., Oxnard, G. R., Dziadziuszko, R., et al. (2015) · New England Journal of Medicine

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 665

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

de Langen, A. J., Johnson, M. L., Mazieres, J., Dingemans, A.-M. C., Mountzios, G., Pless, M., Wolf, J., Schuler, M., Lena, H., Skoulidis, F., et al. (2023) · The Lancet

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 619

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

Shaw, A. T., Riely, G. J., Bang, Y.-J., Kim, D.-W., Camidge, D. R., Solomon, B. J., Varella-Garcia, M., Iafrate, A. J., Shapiro, G. I., Usari, T., et al. (2019) · Annals of Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 576

Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial

Kim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., Riely, G. J., et al. (2016) · The Lancet Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 471

Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer

Lovly, C. M., McDonald, N. T., Chen, H., Ortiz-Cuaran, S., Heukamp, L. C., Yan, Y., Florin, A., Ozretić, L., Lim, D., Wang, L., et al. (2014) · Nature Medicine

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 268

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

Ahn, M.-J., Tanaka, K., Paz-Ares, L., Cornelissen, R., Girard, N., Pons-Tostivint, E., Vicente Baz, D., Sugawara, S., Cobo, M., Pérol, M., et al. (2025) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 244

Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer

Drilon, A., Camidge, D. R., Lin, J. J., Kim, S.-W., Solomon, B. J., Dziadziuszko, R., Besse, B., Goto, K., de Langen, A. J., Wolf, J., et al. (2024) · New England Journal of Medicine

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 240

The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment

Hendry, S. A., Farnsworth, R. H., Solomon, B., Achen, M. G., Stacker, S. A., & Fox, S. B. (2016) · Frontiers in Immunology

Angiogenesis and VEGF in CancerCancer Immunotherapy and Biomarkers

Cited by 188

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.

Hellmann, M. D., Kim, T.-W., Lee, C. B., Goh, B.-C., Miller, W. H., Oh, D.-Y., Jamal, R., Chee, C.-E., Chow, L. Q. M., Gainor, J. F., et al. (2019) · Annals of Oncology

Cancer Immunotherapy and BiomarkersMelanoma and MAPK Pathways

Cited by 174

Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs

Hunter, F. W., Young, R. J., Shalev, Z., Vellanki, R. N., Wang, J., Gu, Y., Joshi, N., Sreebhavan, S., Weinreb, I., Goldstein, D. P., et al. (2015) · Cancer Research

Cancer, Hypoxia, and MetabolismPharmacogenetics and Drug Metabolism

Cited by 82

Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial.

Kim, D.-W., Mehra, R., Tan, D. S.-W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J. F., Sharma, S., De Pas, T., Riely, G. J., et al. (2014) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 57

LBA10 Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study

Johnson, M. L., de Langen, A. J., Waterhouse, D. M., Mazieres, J., Dingemans, A.-M. C., Mountzios, G., Pless, M., Wolf, J., Schuler, M., Lena, H., et al. (2022) · Annals of Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 39

KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC).

Cassier, P. A., Dooms, C. A., Gazzah, A., Felip, E., Steeghs, N., Rohrberg, K. S., De Braud, F. G., Solomon, B. J., Schuler, M. H., Tan, D. S.-W., et al. (2023) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 35

MA06.03 KontRASt-01: Preliminary Safety and Efficacy of JDQ443 + TNO155 in Patients with Advanced, KRAS G12C-Mutated Solid Tumors

Negrao, M. V., Cassier, P. A., Solomon, B., Schuler, M., Rohrberg, K., Cresta, S., Dooms, C., Tan, D. S. W., Loong, H. H.-F., Amatu, A., et al. (2023) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 28

10LBA Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer

Soria, J., Sequist, L. V., Goldman, J. W., Wakelee, H. A., Gadgeel, S. M., Varga, A., Yu, H. A., Solomon, B. J., Ou, S. H., Papadimitrakopoulou, V., et al. (2014) · European Journal of Cancer

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 5